Differential Gene Expression Pattern of Transforming Growth Factor Beta-1 in Early and Advanced Breast Cancers
Heena V Dave*, Manoj J Shah, Shilin N Shukla and Sunil N Trivedi
The Gujarat Cancer & Research Institute, Gujarat, India

Abstract
Background: Transforming Growth Factor Bts (TGF-βs) are pluripotent polypeptides that switch function from growth suppressor to promoter during breast tumorigenesis. This integral function in tumor progression offers it as an attractive target of cancer therapy. Amongst the three mammalian isoforms, TGF-β1 is the most potent, abundant and is considered to be the representative of TGF-β pathway. Higher circulating TGF-β1 is known to affect prognosis, increase relative risk of recurrence and reduced survival in breast cancer. Altered gene expression is determined in breast cancer cell lines; however it is less explored in clinical breast cancer.

Methods: We investigated expression of TGF-β1 with an aim to explore its utility as biomarker. TGF-β1 gene expression was determined from breast cancer patients (N=118) using Real-Time PCR. The relative quantitation was determined by dCt method and differences were expressed as mean fold change (MFC) using GAPDH as endogenous control and adjacent normal tissue of each patient as calibrator. TGF-β1 gene expression was correlated with clinicopathologic prognosticators. Relapse-free and overall survival were assessed by Kaplan-Meier Survival analysis with log-rank test.

Results: TGF-β1 mRNA was downregulated in early stage tumors (1.46 fold) whereas it was upregulated in advanced stage tumors (1.60 fold; p=0.05). Higher downregulation was seen in perimenopausal- than postmenopausal- patients (p=0.022). Node positive and node negative patients exhibited differences in early and advanced tumors (p=0.00001). Ductal carcinoma showed highest downregulation however, linear correlation was seen with grade+++ stromal involvement. Reduced disease-free survival (DFS) was noted in tumors with downregulation and advanced stage than early stage patients.

Conclusion: We conclude that downregulation of TGF-β1 is associated with poor disease-free survival. TGF-β1 may play a significant role in the invasiveness and metastatic potential of breast cancer. The magnitude of downregulation is believed to be responsible for disease progression and can be used as predictive and prognostic marker.

Keywords: Human Breast cancer; TGF-β1 mRNA; Real-Time PCR; Prognosis; Survival

Introduction
Transforming Growth Factor Beta (TGF-β) represents a large family of polypeptides believed to regulate diverse cellular processes like cell proliferation, differentiation, cell motility and adhesion [1]. The actions of TGF-β signaling are mediated soon after the ligands reach to the membrane and bind directly to TGFβ receptor type II (TβRII), which transphosphorylate the type I receptor (TβRI), enabling the phosphorylation of TβRI kinase domain which propels downstream signaling actions through SMAD proteins [2]. TGF-β signaling is thought to be tissue-context and ligand content-dependent. Signals induced by TGF-β are important for growth and development of normal mammary gland development as well as for mammary tumorigenesis [3,4]. In breast cancer pathogenesis, growth-inhibitory effects of TGF-β are featured at early stages of carcinogenesis; however these effects shift to growth-promoting effects with more advanced malignant states [5].

Amongst three mammalian isoforms, TGF-β1 is the first ligand derived from induced growth of anchorage-independent mouse fibroblasts and is reported as an imperative growth regulator of epithelial cells including mammary gland [6]. TGF-β superfamily is comprised of about 60-70 structurally related proteins where TGF-β1 is a prototype of the family. Till date, TGF-β1 is the only and best characterized isoform amongst all [7]. All three ligands (TGF-β1, TGF-β2, TGF-β3) are encoded by unique genes located on various chromosomes; however they share 64% to 85% amino acid sequence homology [8] amongst which, TGF-β1 gene is located on chromosome 19q13 and is expressed as a 25-kDa protein [9].

Majority of studies performed on circulatory TGF-β1 show that higher TGF-β1 was connected to poor prognosis and a progressive disease in many malignancies like breast [10], prostate [11] and hepatocellular carcinoma [12]. Higher serum levels of TGF-β1 shorten overall survival of breast cancer patients [13, 14]. Circulating TGF-β1 was higher in breast cancer patients than healthy individuals; moreover, an increase was seen with advancing stage provoking the shift in its biological role from growth inhibitor to promoter [15,16]. Prognostic utility of TGF-β1 was evaluated from breast cancer cell lines [17] or studies that measured circulatory levels [18,19]. However, very few reports are available where tumoral TGF-β1 either at protein or mRNA level was estimated from clinical human breast cancer. Role of
tumoral TGF-β1 with in human breast carcinoma was assessed where strong immunostaining suggested tumor progression and announced a reduced overall survival [20,21]. Linear association of TGF-β1 with BRCA2 was found to be associated with the prognosis and treatment of breast cancer [22]. Downregulation of TGF-β1 mRNA was also reported in breast [23] and cervical cancer [24]. However, TGF-β1 mRNA expression in human breast cancer prognosis and its relation to clinicopathologic prognosticators, especially with real time RT-PCR, has not yet been published to the best of our knowledge. The only report on estimation of all three TGF-β human isoforms with real time RT-PCR was in laryngeal cancer that has shown their utility as molecular markers in distinguishing cancer from non-neoplastic tissues [25]. In the present study, we investigated TGF-β1 gene expression and compared its transcript levels with disease progression from early to advanced stage breast cancer. The role of TGF-β1 transcript levels was further elucidated by its comparison with clinicopathological prognosticators and survival in breast cancer patients.

Materials and Methods

Patients and disease outcome

This prospective study was approved by the Institutional Ethical Committee and informed consent was obtained from each patient. Previously untreated breast cancer patients [N=118] were randomly enrolled for this study with a mean age of 47 years (Range: 25–80 years). Patients with AJCC TNM stage I and IIA were considered as early stage disease [N=76] [26]. The incidence of clinical factors (Age, Menopausal status) as patient’s characteristics and tumor characteristics (Tumor size, Nodal status, Histologic type, Histologic grade and Stromal involvement) are presented in Table 1. Majority of patients belong to the middle age and postmenopausal groups. Majority of tumors were node positive, having ductal origin, with moderate/poor differentiation and stromal involvement. Remarkably, majority of tumors were aggressive in origin and may result into faster disease progression from early to advanced stage disease. The role of TGF-β1 transcript levels was further elucidated by its comparison with clinicopathological prognosticators and survival in breast cancer patients.

RNA Isolation and purification

Total RNA was extracted from tumor tissues (50 mg) using RNeasy Tissue Kit (Qiagen #74106) and from adjacent normal tissues using (100 mg ) RNeasy Lipid Tissue kit (Qiagen#74804) using manufacturer’s instructions. DNsase digestion was carried out with RNaase–Free DNase set (Qiagen # 79254) as per manufacturer’s instruction. RNA was eluted in RNase-free water. RNA quantitation was performed with spectrophotometer (Multiskan Spectrum, Thermofisher, Finland). Total RNA was then aliquoted and stored at -70°C till further analysis. RNA purity was checked on 1% FA gel using Mini-Sub-Cell GT (B. Braun, Germany) for 5 minutes at 3000 rpm and stored in liquid nitrogen until analysis.

Reverse Transcription and Relative Quantitation of TGF-β1 by Real Time Reverse Transcriptase Polymerase chain Reaction (Real Time RT-PCR)

Five µg total RNA was reverse transcribed using cDNA archive

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Total patients</th>
<th>Early</th>
<th>Advanced</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (Years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 40</td>
<td>28(23.73)</td>
<td>11(26.19)</td>
<td>17(22.37)</td>
</tr>
<tr>
<td>41 – 60</td>
<td>80(67.80)</td>
<td>28(66.67)</td>
<td>52(68.42)</td>
</tr>
<tr>
<td>&gt;60</td>
<td>10(8.47)</td>
<td>03(7.14)</td>
<td>07(9.21)</td>
</tr>
<tr>
<td>Menopausal status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Premenopausal</td>
<td>47(39.83)</td>
<td>16(38.09)</td>
<td>31(40.79)</td>
</tr>
<tr>
<td>Perimenopausal</td>
<td>19(16.10)</td>
<td>03(7.14)</td>
<td>16(21.05)</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td>52(44.07)</td>
<td>23(54.76)</td>
<td>29(38.16)</td>
</tr>
<tr>
<td>Nodal status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Node Negative</td>
<td>53(44.92)</td>
<td>38(90.48)</td>
<td>15(19.74)</td>
</tr>
<tr>
<td>Node positive</td>
<td>65(55.08)</td>
<td>04(9.52)</td>
<td>61(80.26)</td>
</tr>
<tr>
<td>Histologic Type</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ductal Carcinoma</td>
<td>101(85.59)</td>
<td>35(83.33)</td>
<td>66(86.84)</td>
</tr>
<tr>
<td>Lobular Carcinoma</td>
<td>04(3.39)</td>
<td>02(4.76)</td>
<td>02(2.63)</td>
</tr>
<tr>
<td>Others</td>
<td>13(11.02)</td>
<td>05(11.90)</td>
<td>08(10.52)</td>
</tr>
<tr>
<td>Histologic Grade</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well Differentiation</td>
<td>18(15.25)</td>
<td>11(26.19)</td>
<td>07(9.21)</td>
</tr>
<tr>
<td>Moderate+poor Differentiation</td>
<td>100(84.75)</td>
<td>31(73.81)</td>
<td>69(90.79)</td>
</tr>
<tr>
<td>Stromal Involvement</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absent</td>
<td>02(1.69)</td>
<td>00</td>
<td>02(2.63)</td>
</tr>
<tr>
<td>Present</td>
<td>116(98.31)</td>
<td>42(100.0)</td>
<td>74(97.38)</td>
</tr>
<tr>
<td>+</td>
<td>63(54.31)</td>
<td>21(50.00)</td>
<td>42(56.76)</td>
</tr>
<tr>
<td>++</td>
<td>42(36.21)</td>
<td>15(35.71)</td>
<td>27(36.48)</td>
</tr>
<tr>
<td>+++</td>
<td>11(9.48)</td>
<td>06(14.29)</td>
<td>05(6.76)</td>
</tr>
</tbody>
</table>

N=Number of patients; %=Percentage

Table 1: Clinical, Pathological characteristics of 118 breast cancer patients.

kit (Applied Biosystems, Cat #) using manufacturer’s instructions. Real-time quantitative PCR analysis was performed on ABI 7000 sequence detection system (Applied Biosystems) using TaqMan chemistry. Complementary DNA (cDNA) corresponding to 100 ng of total RNA was amplified in a reaction volume of 25μl containing 2X TaqMan Universal Master mix (ABI 4304437) as recommended by the manufacturer. Validated primer-probe mixture was purchased from Applied Biosystems (Part #4331182; TaqMan(R) Gene Expression Assays; (1) TGF-β1: (Hs00171257_m1); (2) ER: (Hs00174860_m1); (3) GAPDH (Glyceraldehyde 3-phosphate Dehydrogenase: (Hs99999905_ml)). Universal thermal cycling conditions were observed which comprised of an initial AmpErase UNG activation step at 50ºC for 2 minutes followed by denaturation step at 95ºC for 10 minutes and 40 cycles at 95ºC for 0.15 minutes and 60ºC for 1 minute. For each patient, the PCR was run in triplicate. The relative expression of the target gene was computed using ddCt method [27] and adjacent non-neoplastic tissue from the same patient as calibrator. The gene expression was expressed as mean fold change (MFC).

Statistical analysis

Statistical analysis was performed using SPSS for Windows (v13.0). The non-parametric Chi-square test was used to compare fold change with clinicopathological variables. The correlation between different parameters was analysed using the non-parametric Spearman’s correlation coefficient. Survival analysis was done with Kaplan-Meier curves using log-rank test. p<0.05 was considered as significant.

Results

In the present study, we assessed TGF-β1 expression in malignant- and in non-malignant- adjacent normal tissues using Real-Time PCR and gene expression was quantitated as the fold change using ddCt method.

Expression of TGF-β1 transcript in the study

TGF-β1 gene was 1.27 fold upregulated in the total cohort of 118 patients. Notably, TGF-β1 was significantly downregulated in early stage patients (1.46 fold) whereas it was upregulated in advanced stage patients (1.60 fold) exhibiting a shift in gene expression. In furtherance, early and advanced stage patients were classified into an upregulation and downregulation of gene expression and all the comparisons were done into four groups: (1) Early stage: Upregulation, (2) Early stage: Downregulation, (3) Advanced stage: Upregulation and (4) Advanced stage: Downregulation. TGF-1 was upregulated in 16.7% (7/42; 2.03 fold) whereas downregulated in 38.3% early stage tumors (35/42; 2.42 fold). Amongst advanced tumors, TGF-β1 was upregulated in 31.6% (24/76; 4.08 fold) whereas downregulated in 68.4% tumors (52/78; 2.18 fold). It has been observed that there was a 2.05 fold increase in the upregulation in 14.9% of patients from Early- stage patients (1.60 fold; p=0.05) exhibiting a shift in gene expression. Notably, TGF-β1 was significantly downregulated in early stage tumors (1.66 fold) as compared to node positive tumors (p=0.00001). Node negative tumors showed a higher downregulation of TGF-β1 in advanced tumors as compared to node positive tumors (p=0.05; Data not shown).

Moreover, TGF-β1 was downregulated in perimenopausal patients (3.66 fold) than postmenopausal patients (2.42 fold) in early stage patients (p=0.002). Node positive and node negative patients exhibited significant downregulation between early versus advanced stages (p=0.00001). Node negative tumors showed a higher downregulation of TGF-β1 in advanced tumors as compared to node positive tumors (p=0.05; Data not shown).

Though majority of tumors were ductal carcinoma (85.59%), downregulation of TGF-β1 was higher in lobular carcinomas than ductal tumors in advanced stage tumors (p=0.036). Remarkably, upregulation of TGF-β1 exhibited an inverse correlation with different histologic types in early stage patients [r=+0.290; p=0.037]. Histologic Grade and downregulated TGF-β1 showed non-uniform pattern between early and advanced stage patients (p=0.040). Highest downregulation was seen in the grade+++ stromal reaction subgroup than grade ++ (p=0.047) in early stage patients whereas in advanced stage tumors, it was upregulated in grade+++ group as compared to grade + (p=0.009) and grade++ (p=0.02). The same observation was also seen in patients with downregulation in grade+++ subgroup than grade ++ (p=0.03).

Comparison of expression patterns of TGF-β1 and ERα

ERα was evaluated in a subset of 110 patients from the same cohort. It was upregulated in 44.5% patients (49/110; 7.02 fold) and downregulated in 55.5% (61/110; 3.61 fold) of patients. On their subgrouping into early- and advanced stage patients, ERα upregulation was evident in 36.7% patients (18/49; 6.52 fold) and downregulated in 34.4% (21/61; 3.95fold). On the other hand, in advanced stage patients ERα was upregulated in 63.3% (31/49; 7.31 fold) whereas downregulated in 65.6% (40/61; 3.44 fold). Then we compared TGF-β1 expression amongst all these subgroups. We found a downregulation of TGF-β1 in early stage tumors irrespective of ERα up- or down- regulation. Conversely, an upregulation of TGF-β1 was seen in advanced stage tumors irrespective of ERα up- or down- regulation (Table 3).

Changes in the expression patterns with disease extension

TGF-β1 was also evaluated from malignant lymph nodes (N=49) and non-malignant lymph nodes (N=22) which would show the differences in the gene expression with disease extension to lymph nodes. TGF-β1 was upregulated by 1.66 fold in tumor tissues and
1.24 fold in their corresponding malignant lymph nodes exhibiting a decrease in the gene expression with disease extension. Moreover, this was compared with the non-malignant lymph nodes (22/49) in which 3 fold increase was noted in non-malignant lymph nodes (4.25 fold; p=0.0037).

**Survival**

TGF-β1 expression was not affecting the Relapse Free Survival (RFS) in the total cohort (p=0.297). Amongst the patients who relapsed, a downregulation of TGF-β1 transcript was seen in 35/51 (68.6%) while an upregulation was evident in 16/51 (31.4%) tumors. Amongst the tumors in which a downregulation of TGF-β1 transcript was seen, the patients with advanced stage relapsed earlier than early stage patients (p=0.078; Figure 2). It was also noticeable that amongst the subgroup of TGF-β1 transcript upregulation, 87.5% patients relapsed who had advanced disease (p=0.219; Figure 3). No differences were seen in the overall survival of the patients in any of the subgroups.

**Discussion**

In the current prospective we have estimated TGF-β1 mRNA with an aim to explore TGF-Beta signaling switch between early and advanced stage patients and tried to find out its possible role in breast cancer progression. Moreover, TGF-β1 mRNA expression was quantitated by highly sensitive real time PCR [27]. Notably, we have used the adjacent normal tissue as calibrator which is obtained from the same patient which would provide the best sample type for comparison. Till date many studies have reported circulating TGF-β1 and its role as a prognostic marker [14-16,18,19]. Circulatory TGF-β1 was higher in breast cancer patients than controls. Moreover, serum TGF-β1 was elevated in advanced stage than early stage patients. High TGF-β1 was also connected to aggressive clinicopathologic prognosticators stamping its role in the progression and metastasis and was also associated with the reduced survival of the patients. These conclusions were drawn in our previous study [13]. In our previous study we had used the same patient’s cohort and estimated circulating serum TGF-β1. We have compared the results and found that protein and mRNA of TGF-β1 did not correlate. This was also reported by Mu et al. [13,28]. Our previous study also reported higher circulating TGF-β1 in breast cancer patients than healthy individuals where TGF-β1 was higher in advanced stage than early stage patients. Elevated serum TGF-β1 was also shown to be linked to aggressive clinicopathological prognosticators and reduced relapse free survival of the breast cancer patients [13].

<table>
<thead>
<tr>
<th>TGF-β1</th>
<th>Early</th>
<th>Advanced</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>MFC</td>
</tr>
<tr>
<td>Estrogen Receptor Upregulation</td>
<td>18</td>
<td>1.61</td>
</tr>
<tr>
<td>Downregulation</td>
<td>21</td>
<td>1.34</td>
</tr>
</tbody>
</table>

* MFC : Mean Fold Change

**Table 3: Correlation between TGF-β1 and Estrogen Receptor α.**
Gorsch et al. [29] demonstrated the immunohistochemical staining of all three TGF-β isoforms in breast cancer to see the impact from any one of them on disease progression and found that TGF-β, staining was connected to the disease aggressiveness. In a study by Ghellal et al. [30] strong association of tumoral TGF-β1 immunostaining was connected to tumor progression, reduced overall survival and an inverse correlation with lymph node involvement. Soula et al. [23] have shown the transcriptional deregulation of TGF-β ligands and their receptors by PCR and western blot analysis where a significant negative correlation was observed between TGF-β1 protein and mRNA by breast tissue-pair analysis.

TGF-β1 mRNA expression with real time PCR has been less explored from clinical human breast cancer samples [31]. Transcripts of TGF-β isoforms have been explored in laryngeal cancer by Karpral et al. [25] who reported its usefulness to demarcate between neoplastic and non-neoplastic tissues. However, in the present study, TGF-β1 transcript was detectable in all breast tumors. A significant downregulation of TGF-β1 was evident in 73.73% patients when compared to respective normal tissues from each patient. To best our knowledge, this is the first study demonstrating a downregulation of TGF-β1 using normal tissue as a calibrator and GAPDH as endogenous control from human breast tumors.

Majority of patients exhibited advanced stage and an aggressive disease. There were 99% tumors with more than 2 cms tumor size and 58.1% patients with >4 positive lymph nodes. The patients therefore were grouped into early- and advanced-stage tumors for further analysis. A significantly different TGF-β1 expression was seen amongst early- and advanced-stage tumors; advanced stage tumors exhibited a higher involvement of TGF-β1 (+2.03 to -2.42 fold). This indicates a higher involvement of TGF-β1 in malignant lymph nodes as compared to primaries. Thus, reduced TGF-β1 expression was seen with an advancement of disease.

Moreover, this study offered us an opportunity to compare TGF-β1 expression in non-malignant- and malignant- lymph nodes. We found that 86.3% non-malignant lymph nodes showed upregulation of TGF-β1. It is hypothesized that ‘such non-malignant’ lymph nodes may harbor ‘occult metastases’. If proven, the breast cancer patients with upregulated TGF-β1 expression in non-malignant lymph nodes may become candidates for aggressive monitoring and subsequent therapeutic intervention with anti TGF-β strategies.

In the current study, we found a down regulation of TGF-β1 transcript and an upregulation in advanced human breast tumors independent of ERα up- or down- regulation. This unique finding may suggest a possibility of identifying such patients as candidates for anti TGF-β strategies.

**Conclusion**

This is the first study that reports TGF-β1 gene expression from a large cohort of Indian breast cancer patients that demonstrate its prognostic and predictive utility. 'TGF-β1 switch' was evident; however, downregulation was associated with a reduced relapse free survival of breast cancer patients.

**Acknowledgement**

The study was partly supported by the funding from Indian Council of Medical research (Indo-German collaborative project) and The Gujarat Cancer Society, Ahmedabad, India.

**Ethical Committee Approval**

All procedures were approved by the institutional ethics committee and informed consent was obtained from all subjects.

**Conflict of interest statement**

None of the authors have any conflict of interest related to this manuscript.

**References**


